Floatz logo

Ad-Rts-Hil-12

Pediatric Brain Tumor

Alaunos TherapeuticsPhase 1/2Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
95/ 100

Competitive context

62 Active assets in the Pediatric Brain Tumor cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
Temsirolimus
M.D. Anderson Cancer Center
Phase 2BBB
Sorafenib
National Cancer Institute (NCI)
Phase 2BB
Bxcl501
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
Nivolumab
InSightec
Phase 3BB

View all 50 →

Same molecule, other indications

Ad-Rts-Hil-12 is also rated in:

breast cancerDormant
CC
Indicative ·
44 / 100
View asset →
glioblastomaDormant
CC
Indicative ·
42 / 100
View asset →
diffuse intrinsic pontine gliomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →